204 related articles for article (PubMed ID: 34639851)
1. IQOS Marketing in the US: The Need to Study the Impact of FDA Modified Exposure Authorization, Marketing Distribution Channels, and Potential Targeting of Consumers.
Berg CJ; Abroms LC; Levine H; Romm KF; Khayat A; Wysota CN; Duan Z; Bar-Zeev Y
Int J Environ Res Public Health; 2021 Oct; 18(19):. PubMed ID: 34639851
[TBL] [Abstract][Full Text] [Related]
2. IQOS Marketing Strategies and Expenditures in the United States From Market Entrance in 2019 to Withdrawal in 2021.
Duan Z; Levine H; Romm KF; Bar-Zeev Y; Abroms LC; Griffith L; Wang Y; Khayat A; Cui Y; Berg CJ
Nicotine Tob Res; 2023 Sep; 25(11):1798-1803. PubMed ID: 37338204
[TBL] [Abstract][Full Text] [Related]
3. FDA's reduced exposure marketing order for IQOS: why it is not a reliable global model.
Lempert LK; Bialous S; Glantz S
Tob Control; 2022 Aug; 31(e1):e83-e87. PubMed ID: 33811155
[TBL] [Abstract][Full Text] [Related]
4. IQOS marketing strategies in the USA before and after US FDA modified risk tobacco product authorisation.
Berg CJ; Romm KF; Bar-Zeev Y; Abroms LC; Klinkhammer K; Wysota CN; Khayat A; Broniatowski DA; Levine H
Tob Control; 2023 Jul; 32(4):418-427. PubMed ID: 34667105
[TBL] [Abstract][Full Text] [Related]
5. Brief report on IQOS point-of-sale marketing, promotion and pricing in IQOS retail partner stores in Atlanta, Georgia, USA.
Henderson KC; Van Do V; Wang Y; Duan Z; Popova L; Spears CA; Weaver SR; Ashley DL; Barker DC; Huang J
Tob Control; 2023 Aug; 32(e2):e260-e264. PubMed ID: 35918133
[TBL] [Abstract][Full Text] [Related]
6. IQOS point-of-sale marketing strategies in Israel: a pilot study.
Bar-Zeev Y; Levine H; Rubinstein G; Khateb I; Berg CJ
Isr J Health Policy Res; 2019 Jan; 8(1):11. PubMed ID: 30642383
[TBL] [Abstract][Full Text] [Related]
7. Heated tobacco products likely appeal to adolescents and young adults.
McKelvey K; Popova L; Kim M; Chaffee BW; Vijayaraghavan M; Ling P; Halpern-Felsher B
Tob Control; 2018 Nov; 27(Suppl 1):s41-s47. PubMed ID: 30352843
[TBL] [Abstract][Full Text] [Related]
8. Assessment of IQOS Marketing Strategies at Points-of-Sale in Israel at a Time of Regulatory Transition.
Bar-Zeev Y; Berg CJ; Abroms LC; Rodnay M; Elbaz D; Khayat A; Levine H
Nicotine Tob Res; 2022 Jan; 24(1):100-108. PubMed ID: 34216461
[TBL] [Abstract][Full Text] [Related]
9. United States Food and Drug Administration's authorization of reduced exposure claims for IQOS
Eckford R; Severini G; Sebrié EM; Muggli ME; Beem A; Rosen D; Crosbie E
Rev Panam Salud Publica; 2022; 46():e155. PubMed ID: 36245905
[TBL] [Abstract][Full Text] [Related]
10. Impact of FDA endorsement and modified risk versus exposure messaging in IQOS ads: a randomised factorial experiment among US and Israeli adults.
Berg CJ; Duan Z; Wang Y; Thrasher JF; Bar-Zeev Y; Abroms LC; Romm KF; Khayat A; Levine H
Tob Control; 2024 Mar; 33(e1):e69-e77. PubMed ID: 36428095
[TBL] [Abstract][Full Text] [Related]
11. Correlates of Perceptions, Use, and Intention to Use Heated Tobacco Products Among US Young Adults in 2020.
Duan Z; Wysota CN; Romm KF; Levine H; Bar-Zeev Y; Choi K; Berg CJ
Nicotine Tob Res; 2022 Nov; 24(12):1968-1977. PubMed ID: 35901840
[TBL] [Abstract][Full Text] [Related]
12. Content analysis of IQOS direct mail and email marketing in the US.
Henderson KC; Kute NG; Popova L; Ashley DL; Spears CA; Churchill V; Weaver SR; Pechacek TF; Huang J
Prev Med Rep; 2024 Feb; 38():102634. PubMed ID: 38375169
[TBL] [Abstract][Full Text] [Related]
13. Effects of IQOS health warnings and modified risk claims among young adult cigarette smokers and non-smokers.
Mays D; Johnson AC; Glasser A; Mercincavage M; Strasser AA
Tob Control; 2023 Jul; 32(4):505-508. PubMed ID: 34716283
[TBL] [Abstract][Full Text] [Related]
14. Unboxed: US Young Adult Tobacco Users' Responses to a New Heated Tobacco Product.
Kim M; Watkins SL; Koester KA; Mock J; Kim HC; Olson S; Harvanko AM; Ling PM
Int J Environ Res Public Health; 2020 Nov; 17(21):. PubMed ID: 33153143
[TBL] [Abstract][Full Text] [Related]
15. Awareness, experience and prevalence of heated tobacco product, IQOS, among young Korean adults.
Kim J; Yu H; Lee S; Paek YJ
Tob Control; 2018 Nov; 27(Suppl 1):s74-s77. PubMed ID: 30158210
[TBL] [Abstract][Full Text] [Related]
16. PMI's heated tobacco products marketing claims of reduced risk and reduced exposure may entice youth to try and continue using these products.
McKelvey K; Baiocchi M; Halpern-Felsher B
Tob Control; 2020 Dec; 29(e1):e18-e24. PubMed ID: 32029537
[TBL] [Abstract][Full Text] [Related]
17. IQOS marketing strategies at point-of-sales: a cross-sectional survey with retailers.
Bar-Zeev Y; Berg CJ; Khayat A; Romm KF; Wysota CN; Abroms LC; Elbaz D; Levine H
Tob Control; 2023 Aug; 32(e2):e198-e204. PubMed ID: 35140170
[TBL] [Abstract][Full Text] [Related]
18. Revolution or redux? Assessing IQOS through a precursor product.
Elias J; Dutra LM; St Helen G; Ling PM
Tob Control; 2018 Nov; 27(Suppl 1):s102-s110. PubMed ID: 30305324
[TBL] [Abstract][Full Text] [Related]
19. Creating a market for IQOS: analysis of Philip Morris' strategy to introduce heated tobacco products to the Australian consumer market.
Watts C; Burton S; Freeman B
Tob Control; 2022 May; 31(3):458-463. PubMed ID: 33191270
[TBL] [Abstract][Full Text] [Related]
20. How Media Stories in Low- and Middle-Income Countries Discussed the U.S. Food and Drug Administration's Modified Risk Tobacco Product Order for IQOS.
Robichaud MO; Puryear T; Cohen JE; Kennedy RD
Nicotine Tob Res; 2023 Aug; 25(10):1659-1666. PubMed ID: 37310968
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
